Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
01 déc. 2022 16h01 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 nov. 2022 18h33 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
08 nov. 2022 07h18 HE
|
Fulcrum Therapeutics, Inc.
― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) ― ― Presented 96-week data from the Phase 2 ReDUX4 trial open label extension (OLE) study...
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
07 nov. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
— Santiago Arroyo, M.D., Ph.D. joined as CMO on November 7, 2022 — — Jeff W. Jacobs, Ph.D. to join as CSO on December 1, 2022 — CAMBRIDGE, Mass. –, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum...
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
02 nov. 2022 07h05 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
01 nov. 2022 17h29 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
12 oct. 2022 07h30 HE
|
Fulcrum Therapeutics, Inc.
- 96-week findings support losmapimod as a disease-modifying therapy for FSHD - U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - Industry Symposium on October 12,...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 oct. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 sept. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
06 sept. 2022 16h01 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...